Clinical and economic aspects of using a novel Russian non-nucleoside reverse transcriptase inhibitor elsulfavirine as a first-line treatment of HIV infection in patients starting antiretroviral therapy for the first time
|
01.01.2018 |
Ryazhenov V.
Gorokhova S.
|
Infektsionnye Bolezni |
|
0 |
Ссылка
© 2018 Dynasty Publishing House. All rights reserved. The objective. To perform a budget impact analysis of a novel antiretroviral drug elsulfavirine (ESV) compared with currently used medical technologies. Materials and methods. The pharmacoeconomic model was based on the studies of efficacy and safety of two non-nucleoside reverse transcriptase inhibitors: ESV and rilpivirine (RPV) combined with standard basic tenofovir/ emtricitabine (TDF/FTC) therapy for 48 weeks. The studies were performed in similar clinical settings. The budget impact analysis assessed only direct medical costs of antiretroviral drugs within the chosen strategies of first-line antiretroviral therapy (ART). Results. It was shown that the treatment of ART-naive HIV patients with ESV is associated with 61,234.88 RUB less costs per patient in a 48-week course compared with RPV treatment. The analyzed values of cost effectiveness were lower for ESV strategy than for the strategy with the use of RPV. It makes ESV a more cost-efficient option within the developed model. Conclusion. The use of ESV is a preferable strategy of a first-line treatment of HIV. It is associated with less financial costs and more preferable cost effectiveness rate.
Читать
тезис
|
Antiretrovirus therapy - A new epoch of prevention of HIV infection
|
01.01.2018 |
Tursunov R.
Kanestri V.
Simonova E.
Raichich R.
|
HIV Infection and Immunosuppressive Disorders |
|
1 |
Ссылка
© 2018. Modern medicine, relying on a verified strategy and consistent approach, has proved that to date, HIV infection, thanks to effective antiretroviral therapy, has evolved from a category of incurable and deadly diseases into a nosology potentially controlled by medical and diagnostic measures. Moreover, as shown by numerous studies, not only clinical, but also the population effect has been achieved. The life expectancy of HIV-infected people has increased, its quality has significantly improved, and the number of potential sources of infection has decreased. The concept of «treatment as prevention» at the present stage becomes an integral part of the complex of measures to combat HIV infection, since the early onset of ART can significantly reduce the risk of transmission of the pathogen, as well as the level of AIDS-associated morbidity and mortality. In addition to ART, the principles of comprehensive prevention remain unshakable, taking into account the modern epidemiological features of HIV infection.
Читать
тезис
|